Skip to main content
Top
Published in: Diabetologia 8/2019

01-08-2019 | Insulins | Article

Androgens sensitise mice to glucocorticoid-induced insulin resistance and fat accumulation

Authors: Sylvia J. Gasparini, Michael M. Swarbrick, Sarah Kim, Lee J. Thai, Holger Henneicke, Lauryn L. Cavanagh, Jinwen Tu, Marie-Christin Weber, Hong Zhou, Markus J. Seibel

Published in: Diabetologia | Issue 8/2019

Login to get access

Abstract

Aims/hypothesis

Chronic glucocorticoid therapy causes insulin resistance, dyslipidaemia, abnormal fat accumulation, loss of muscle mass and osteoporosis. Here we describe a hitherto unknown sexual dimorphism in the metabolic response to chronic glucocorticoid exposure in mice. This led us to investigate whether glucocorticoid-induced insulin resistance and obesity were dependent on sex hormones.

Methods

Male and female CD1 mice were treated for 4 weeks with supraphysiological doses (~250 μg/day) of corticosterone, the main glucocorticoid in rodents, or equivalent volume of vehicle (drinking water without corticosterone). To investigate the effects of sex hormones, a separate group of mice were either orchidectomised or ovariectomised prior to corticosterone treatment, with or without dihydrotestosterone replacement. Body composition was determined before and after corticosterone treatment, and insulin tolerance was assessed after 7 and 28 days of treatment. Adipocyte morphology was assessed in white and brown adipose tissues by immunohistochemistry, and fasting serum concentrations of NEFA, triacylglycerols, total cholesterol and free glycerol were measured using colorimetric assays. Obesity- and diabetes-related hormones were measured using multiplex assays, and RNA and protein expression in adipose tissues were measured by RT-PCR and immunoblotting, respectively.

Results

Chronic corticosterone treatment led to insulin resistance, fasting hyperinsulinaemia, increased adiposity and dyslipidaemia in male, but not female mice. In males, orchidectomy improved baseline insulin sensitivity and attenuated corticosterone-induced insulin resistance, but did not prevent fat accumulation. In androgen-deficient mice (orchidectomised males, and intact and ovariectomised females) treated with dihydrotestosterone, corticosterone treatment led to insulin resistance and dyslipidaemia. In brown adipose tissue, androgens were required for corticosterone-induced intracellular lipid accumulation (‘whitening’), and dihydrotestosterone specifically exacerbated corticosterone-induced accumulation of white adipose tissue by increasing adipocyte hypertrophy. Androgens also suppressed circulating adiponectin concentrations, but corticosterone-induced insulin resistance did not involve additional suppression of adiponectin levels. In white adipose tissue, androgens were required for induction of the glucocorticoid target gene Gilz (also known as Tsc22d3) by corticosterone.

Conclusions/interpretation

In mice, androgens potentiate the development of insulin resistance, fat accumulation and brown adipose tissue whitening following chronic glucocorticoid treatment.
Appendix
Available only for authorised users
Literature
7.
go back to reference Grundy SM (1999) Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 83:25F–29FCrossRefPubMed Grundy SM (1999) Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 83:25F–29FCrossRefPubMed
8.
go back to reference Magomedova L, Cummins CL (2016) Glucocorticoids and metabolic control. Handb Exp Pharmacol 233:73–93CrossRefPubMed Magomedova L, Cummins CL (2016) Glucocorticoids and metabolic control. Handb Exp Pharmacol 233:73–93CrossRefPubMed
12.
go back to reference Strack AM, Bradbury MJ, Dallman MF (1995) Corticosterone decreases nonshivering thermogenesis and increases lipid storage in brown adipose tissue. Am J Phys 268:R183–R191 Strack AM, Bradbury MJ, Dallman MF (1995) Corticosterone decreases nonshivering thermogenesis and increases lipid storage in brown adipose tissue. Am J Phys 268:R183–R191
21.
go back to reference Duma D, Collins JB, Chou JW, Cidlowski JA (2010) Sexually dimorphic actions of glucocorticoids provide a link to inflammatory diseases with gender differences in prevalence. Sci Signal 3:ra74CrossRefPubMedPubMedCentral Duma D, Collins JB, Chou JW, Cidlowski JA (2010) Sexually dimorphic actions of glucocorticoids provide a link to inflammatory diseases with gender differences in prevalence. Sci Signal 3:ra74CrossRefPubMedPubMedCentral
22.
go back to reference Spaanderman DCE, Nixon M, Buurstede JC et al (2018) Androgens modulate glucocorticoid receptor activity in adipose tissue and liver. J Endocrinol 240(1):51–63 Spaanderman DCE, Nixon M, Buurstede JC et al (2018) Androgens modulate glucocorticoid receptor activity in adipose tissue and liver. J Endocrinol 240(1):51–63
36.
go back to reference Cai C, He HH, Chen S et al (2011) Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20:457–471CrossRefPubMedPubMedCentral Cai C, He HH, Chen S et al (2011) Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20:457–471CrossRefPubMedPubMedCentral
46.
go back to reference Ganie MA, Khurana ML, Nisar S et al (2013) Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab 98(9):3599–3607. https://doi.org/10.1210/jc.2013-1040 CrossRefPubMed Ganie MA, Khurana ML, Nisar S et al (2013) Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab 98(9):3599–3607. https://​doi.​org/​10.​1210/​jc.​2013-1040 CrossRefPubMed
Metadata
Title
Androgens sensitise mice to glucocorticoid-induced insulin resistance and fat accumulation
Authors
Sylvia J. Gasparini
Michael M. Swarbrick
Sarah Kim
Lee J. Thai
Holger Henneicke
Lauryn L. Cavanagh
Jinwen Tu
Marie-Christin Weber
Hong Zhou
Markus J. Seibel
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 8/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-4887-0

Other articles of this Issue 8/2019

Diabetologia 8/2019 Go to the issue

Up Front

Upfront

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.